DiVerential eVects of low-dose decitabine on immune eVector and suppressor responses in melanoma-bearing mice

Cancer Immunology, Immunotherapy

Volumn 61, Issue 9, 2012, Pages 1441-1450

  Triozzi, Pierre L ^a   Aldrich, Wayne ^a   Achberger, Susan ^a   Ponnazhagan, Selvarangan ^b   Alcazar, Oscar ^a   Saunthararajah, Yogen ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Hypomethylation; Immunotherapy; Myeloid suppressor cells; Regulatory T cells

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ADENOVIRUS VECTOR; CYTOKINE; INTERLEUKIN 2; MELANOMA ANTIGEN; MELANOMA ANTIGEN TRP2; MELANOMA VACCINE; MELANOMA VACCINE AAV DCT; ODN 1826; TOLL LIKE RECEPTOR AGONIST; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; CPG ODN 1826; DRUG DERIVATIVE; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW CELL; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG TARGETING; EFFECTOR CELL; FLOW CYTOMETRY; IMMUNE EFFECTOR RESPONSE; IMMUNE RESPONSE; IMMUNE SUPPRESSOR RESPONSE; IMMUNOMODULATION; LYMPHOID CELL; M1 POLARIZATION; MACROPHAGE; MELANOMA; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; POLARIZATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TUMOR IMMUNOLOGY; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DOSE RESPONSE; DRUG POTENTIATION; EXPERIMENTAL MELANOMA; FEMALE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTOR 9;

EID: 84866565997     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1204-x     Document Type: Article

References (48)

1. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, Garrido F (2001) Re-expression of HLA class I antigens and restoration of antigen-speciWc CTL response in melanoma cells following 5-aza-2-deoxycytidine treatment. Int J Cancer 94:243-251 (Pubitemid 32911420)
2. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordón-Cardó C, Lowe SW (2001) Inactivation of the apoptosis eVector Apaf-1 in malignant melanoma. Nature 409:207-211 (Pubitemid 32144287)
3. Tomasi TB, Magner WJ, Khan AN (2006) Epigenetic regulation of immune escape genes in cancer. Cancer Immunol Immunother 55:1159-1184 (Pubitemid 43992044)
4. Gollob JA, Sciambi CJ, Peterson BL, Richmond T, Thoreson M, Moran K, Dressman HK, Jelinek J, Issa JP (2006) Phase I trial of sequential low-dose 5-aza-2-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 12:4619-4627
5. http://clinicaltrials.gov/ct2/show/NCT00791271
6. Kozar K, Kamijski R, Switaj T, Oidak T, Machaj E, Wysocki PJ, Mackiewicz A, Lasek W, Jakóbisiak M, Goiab J (2003) Interleukin 12-based immunotherapy improves the antitumor eVectiveness of a low-dose 5-Aza-2-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice. Clin Cancer Res 9:3124-3133
7. Lu D, Hoory T, Monie A, Wu A, Wang MC, Hung CF (2009) Treatment with demethylating agent, 5-aza-2-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine 27: 4363-4369
8. Sánchez-Abarca LI, Gutierrez-Cosio S, Santamaría C, Caballero-Velazquez T, Blanco B, Herrero-Sánchez C, García JL, Carrancio S, Hernández-Campo P, González FJ, Flores T, Ciudad L, Ballestar E, Del Cañizo C, San Miguel JF, Pérez-Simon JA (2010) Immunomodulatory eVect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 115:107-121
9. Santourlidis S, Trompeter HI, Weinhold S, Eisermann B, Meyer KL, Wernet P, Uhrberg M (2002) Crucial role of DNA methylation in determination of clonally distributed killer cell Ig-like receptor expression patterns in NK cells. J Immunol 169:4253-4261 (Pubitemid 35178197)
10. Kim HP, Leonard WJ (2007) CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J Exp Med 204:1543-1551 (Pubitemid 47048022)
11. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, SoiVer RJ, Frank DA, Ritz J (2006) IL-2 regulates FOXP3 expression in human CD4+ CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108:1571-1579 (Pubitemid 44316124)
12. Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, Piwnica-Worms DR, DiPersio JF (2010) In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacriWcing graft-versus-leukemia. Blood 116:129-139
13. Ogbomo H, Michaelis M, Kreuter J, Doerr HW, Cinatl J Jr (2007) Histone deacetylase inhibitors suppress natural killer cell cytolytic activity. FEBS Lett 581:1317-1322 (Pubitemid 46452605)
14. Liu Y, Kuick R, Hanash S, Richardson B (2009) DNA methylation inhibition increases T cell KIR expression through eVects on both promoter methylation and transcription factors. Clin Immunol 130:213-224
15. Moreira JM, Scheipers P, Sorensen P (2003) The histone deacetylase inhibitor trichostatin A modulates CD4+ T cell responses. BMC Cancer (http://www.biomedcentral.com/1471-2407/3/30)
16. Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, Reid SP, Levy DE, Bromberg JS (2009) Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 182:259-273
17. Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, Cohen D, Huang Q (2007) Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 eVector cell function. Blood 109:1123-1130 (Pubitemid 46220659)
18. Kozlowska A, Jagodzinski PP (2006) EVect of trichostatin A on CD4 surface density in peripheral blood T cells. Folia Histochem Cytobiol 44:259-262 (Pubitemid 44696966)
19. Guo L, Hu-Li J, Zhu J, Watson CJ, DiWlippantonio MJ, Pannetier C, Paul WE (2002) In TH2 cells the Il4 gene has a series of accessibility states associated with distinctive probabilities of IL-4 production. Proc Natl Acad Sci USA 99:10623-10628
20. Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, Wright KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E, Sotomayor EM (2008) The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 10:92-100
21. Fourcade J, Kudela P, Andrade Filho PA, Janjic B, Land SR, Sander C, Krieg A, Donnenberg A, Shen H, Kirkwood JM, Zarour HM (2008) Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-speciWc CD8+ T cells in melanoma patients. J Immunother 31:781-791
22. Pashenkov M, Goëss G, Wagner C, Hörmann M, Jandl T, Moser A, Britten CM, Smolle J, Koller S, Mauch C, Tantcheva-Poor I, Grabbe S, Loquai C, Esser S, Franckson T, Schneeberger A, Haarmann C, Krieg AM, Stingl G, Wagner SN (2006) Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 24:5716-5724 (Pubitemid 46631314)
23. Krieg AM (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5:471-484 (Pubitemid 44136959)
24. Triozzi PL, Aldrich A, Ponnazhagan S (2010) Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists. Vaccine 28:7837-7843
25. Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, Druker BJ, Deininger MW (2007) A half-log increase in BCRABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 13:6136-6143 (Pubitemid 350075073)
26. Alcazar O, Achberger S, Aldrich W, Hu Z, Negrotto S, Saunthararajah Y, Triozzi PL (2011) Epigenetic regulation of melanoma diVerentiation in vitro and in vivo. doi:10.1002/ijc.26320
27. Rothhammer T, BosserhoV AK (2007) Epigenetic events in malignant melanoma. Pigment Cell Res 20:92-111 (Pubitemid 46439524)
28. Buhtoiarov IN, Sondel PM, EickhoV JC, Rakhmilevich AL (2007) Macrophages are essential for antitumour eVects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides. Immunology 120:412-423 (Pubitemid 46232916)
29. Koschmieder S, Agrawal S, Radomska HS, Huettner CS, Tenen DG, Ottmann OG, Berdel WE, Serve HL, Müller-Tidow C (2007) Decitabine and vitamin D3 diVerentially aVect hematopoietic transcription factors to induce monocytic diVerentiation. Int J Oncol 30:349-355
30. Laurenzana A, Petruccelli LA, Pettersson F, Figueroa ME, Melnick A, Baldwin AS, Paoletti F, Miller WH Jr (2009) Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic diVerentiation in acute myeloid leukemia cells. Cancer Res 69:55-64
31. Daurkin I, Eruslanov E, Vieweg J, Kusmartsev S (2010) Generation of antigen-presenting cells from tumor-inWltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2-deoxycytidine. Cancer Immunol Immunother 59:697-706
32. Schmiedel BJ, Arélin V, Gruenebach F, Krusch M, Schmidt SM, Salih HR (2011) Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer 128:2911-2922
33. Schmudde M, Friebe E, Sonnemann J, Beck JF, Bröker BM (2010) Histone deacetylase inhibitors prevent activation of tumourreactive NK cells and T cells but do not interfere with their cytolytic eVector functions. Cancer Lett 295:173-181
34. Moon C, Kim SH, Park KS, Choi BK, Lee HS, Park JB, Choi GS, Kwan JH, Joh JW, Kim SJ (2009) Use of epigenetic modiWcation to induce FOXP3 expression in naïve T cells. Transplant Proc 41:1848-1854
35. Werneck MB, Lugo-Villarino G, Hwang ES, Cantor H, Glimcher LH (2008) T-bet plays a key role in NK-mediated control of melanoma metastatic disease. J Immunol 180:8004-8010
36. Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni TB, Salumbides BC, Van Erp K, Schulick R, Pili R (2007) Synergistic in vivo antitumor eVect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res 13(15 Pt 1):4538-4546 (Pubitemid 47219724)
37. Balkwill F, Mantovani A (2001) InXammation and cancer: back to Virchow? Lancet 357:539-545
38. Santoso B, Ortiz BD, Winoto A (2000) Control of organ-speciWc demethylation by an element of the T-cell receptor-alpha locus control region. J Biol Chem 275:1952-1958 (Pubitemid 30060821)
39. Rehli M (2002) Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 23:375-378 (Pubitemid 34804626)
40. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 10:987-995 (Pubitemid 41057715)
41. Sica A, Saccani A, Bottazzi B, Polentarutti N, Vecchi A, van Damme J, Mantovani A (2000) Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumorassociated macrophages. J Immunol 164:762-767 (Pubitemid 30043699)
42. Clarke JH, Cha JY, Walsh MD, Gamboni-Robertson F, Banerjee A, Reznikov LL, Dinarello CA, Harken AH, McCarter MD (2005) Melanoma inhibits macrophage activation by suppressing toll-like receptor 4 signaling. J Am Coll Surg 201:418-425 (Pubitemid 41206781)
43. Wang YC, He F, Feng F, Liu XW, Dong GY, Qin HY, Hu XB, Zheng MH, Liang L, Feng L, Liang YM, Han H (2010) Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res 70:4840-4849
44. Hara I, Nguyen H, Takechi Y, Gansbacher B, Chapman PB, Houghton AN (1995) Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int J Cancer 61:253-260
45. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181:5791-5802
46. Melencio L, McKallip RJ, Guan H, Ramakrishnan R, Jain R, Nagarkatti PS, Nagarkatti M (2006) Role of CD4(+)CD25(+) T regulatory cells in IL-2-induced vascular leak. Int Immunol 18:1461-1471 (Pubitemid 44446824)
47. Piras F, Colombari R, Minerba L, Murtas D, Floris C, Maxia C, Corbu A, Perra MT, Sirigu P (2005) The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 104:1246-1254 (Pubitemid 41278960)
48. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L (2007) IdentiWcation of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony stimulation factor-based antitumor vaccine. J Clin Oncol 25:2546-2553 (Pubitemid 47041228)